# Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

> **NCT02999178** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 663 (actual)

## Conditions studied

- Lung Diseases, Interstitial

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02999178
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-17
- **Primary completion:** 2019-04-23
- **Final completion:** 2019-08-12
- **Target enrollment:** 663 (ACTUAL)
- **Last updated:** 2020-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02999178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02999178, "Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02999178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*